EPS for Trillium Therapeutics Inc. (TRIL) Expected At $-0.66

August 9, 2018 - By Billy Entrekin

Analysts expect Trillium Therapeutics Inc. (NASDAQ:TRIL) to report $-0.66 EPS on August, 10.They anticipate $0.33 EPS change or 33.33 % from last quarter’s $-0.99 EPS. After having $-0.51 EPS previously, Trillium Therapeutics Inc.’s analysts see 29.41 % EPS growth. The stock increased 2.97% or $0.15 during the last trading session, reaching $5.2. About 13,005 shares traded. Trillium Therapeutics Inc. (NASDAQ:TRIL) has risen 11.93% since August 9, 2017 and is uptrending. It has underperformed by 0.64% the S&P500.

Trillium Therapeutics Inc. (NASDAQ:TRIL) Ratings Coverage

Among 2 analysts covering Trillium Therapeutics (NASDAQ:TRIL), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Trillium Therapeutics had 3 analyst reports since March 12, 2018 according to SRatingsIntel. Leerink Swann initiated Trillium Therapeutics Inc. (NASDAQ:TRIL) on Friday, April 13 with “Hold” rating. As per Monday, May 14, the company rating was maintained by H.C. Wainwright. The stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) earned “Buy” rating by H.C. Wainwright on Monday, March 12.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company has market cap of $70.91 million. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. It currently has negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.

More recent Trillium Therapeutics Inc. (NASDAQ:TRIL) news were published by: Seekingalpha.com which released: “Company Spotlight: Trillium Therapeutics” on July 18, 2018. Also Seekingalpha.com published the news titled: “Company Profile: Surface Oncology” on July 22, 2018. Globenewswire.com‘s news article titled: “Trillium Therapeutics Reports Second Quarter 2018 Financial and Operating Results” with publication date: August 08, 2018 was also an interesting one.

Trillium Therapeutics Inc. (NASDAQ:TRIL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.